|Boston Scientific has launched its Cognis CRT-D in China.--Courtesy of Boston Scientific|
Boston Scientific ($BSX) has launched its Cognis CRT-D device in China, part of the company's ongoing efforts to capitalize on emerging markets and right the ship of sales.
Cognis CRT-D is the world's thinnest implant of its kind, Boston Scientific said, and its Chinese launch follows approvals in the U.S. and Europe. The device, recently boasting a 10-year lifespan, features 6 pacing configurations alongside the company's HF Perspectiv suite of diagnostics, technology that allows physicians to chart how patients respond to cardiac resynchronization therapy.
Boston Scientific's global defibrillator sales continue to sag, dropping another 3% last quarter to $213 million, part of a 2% swoon for the company's rhythm management business. However, Boston Scientific increased its emerging markets revenue by 29% on the quarter, deepening its presence in Brazil, Russia, India and China as it plots a turnaround.
A renewed focus on emerging markets is one facet of CEO Mike Mahoney's plan to reverse Boston Scientific's fortunes, coming alongside thousands of job cuts and a fair amount of M&A.
And while the process has hardly been painless--the company took a $354 million net loss in the first quarter--Boston Scientific's recent acquisitions in electrophysiology and renal denervation have analysts excited about future gains, and technologies like Watchman and Lotus have been posting strong data on the way to regulatory approvals.
- read the announcement